Cereno Scientific to Attend Major Biotech Events in 2026
GOTHENBURG, Sweden – Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech company that develops treatments to improve and prolong life for those facing rare cardiovascular and pulmonary illnesses, is set to participate in JPM Week 2026 and the Biotech Showcase from January 12 to January 18, 2026.
Overview of JPM Week
The JPM Week stands as the premier annual gathering for stakeholders in the global life sciences arena. It attracts a diverse group of participants, including biotechnology firms, pharmaceutical companies, investors, analysts, patient advocacy organizations, and industry professionals. The event coincides with the prestigious J.P. Morgan Healthcare Conference, which features numerous satellite events, partnership discussions, and corporate presentations spread throughout the vibrant San Francisco area.
Engagement and Presentations
Cereno Scientific will engage in multiple meetings over the course of the week. Additionally, they will have a presence at the Biotech Showcase, an essential investor and partnering event running from January 12 to January 14, perfectly aligned with the J.P. Morgan conference activities, fostering vital connections within the industry.
Sten R. Sörensen, CEO of Cereno Scientific, expressed, "Our involvement in JPM Week is a significant highlight of our annual schedule, allowing us to connect with the global biotech community during one of the sector's most influential events. This past year has seen substantial advancements in our HDAC inhibitor portfolio. We are excited to share our progress, especially the advancement of our lead candidate CS1 as we move toward a global Phase IIb trial in pulmonary arterial hypertension (PAH), alongside impressive Phase I data for CS014 as it transitions to Phase II. We're eager to foster new partnerships, attract investors, and broaden our scientific discussions. Our goal of delivering disease-modifying treatments to those affected by rare cardiovascular and pulmonary diseases remains our top priority."
Contacting Cereno Scientific
Those interested in discussing potential collaborations with Cereno Scientific can reach out through their dedicated communication channels. The company's team is open for inquiries via their partnered platforms during the Biotech Showcase.
About Cereno Scientific AB
Cereno Scientific is at the forefront of developing innovative therapies aimed at enhancing and extending life expectancy. Their pipeline showcases pioneering drug candidates designed to treat people living with rare cardiovascular and pulmonary conditions, empowering them to lead fulfilling lives.
The lead candidate, CS1, acts as an HDAC inhibitor targeting the root causes of pulmonary arterial hypertension (PAH) through epigenetic modulation. This well-tolerated oral treatment has demonstrated a favorable safety profile and encouraging efficacy results during its Phase IIa trial, indicating improvements in vascular remodeling and right heart function alongside enhanced quality of life for patients. Patients who successfully completed the Phase IIa trial can gain access to CS1 through an Expanded Access Program.
Additionally, Cereno Scientific is advancing CS014, a new chemical entity identified for its potential in treating underlying disease mechanisms associated with rare cardiovascular and pulmonary disorders, like idiopathic pulmonary fibrosis (IPF), based on its positive Phase I trial results.
The company is also investigating CS585, an oral receptor agonist showing promise for treating cardiovascular conditions through a multimodal mechanism, although it has yet to receive a clinical development designation. Preclinical results suggest potential uses, such as thrombosis prevention without a heightened bleeding risk, showcasing their commitment to addressing unmet medical needs.
Headquartered at the GoCo Health Innovation City in Gothenburg, Sweden, Cereno Scientific also operates a subsidiary in Boston, Massachusetts. The company is a publicly traded entity on the Nasdaq First North under the ticker symbol CRNO B.
Frequently Asked Questions
What is the significance of Cereno Scientific's participation in JPM Week?
Participation in JPM Week allows Cereno Scientific to connect with industry leaders, potential investors, and partners to further their mission to treat rare cardiovascular and pulmonary diseases.
What does Cereno Scientific specialize in?
Cereno Scientific develops innovative treatments that target rare cardiovascular and pulmonary diseases, focusing on improving and extending patients' lives.
When is the Biotech Showcase happening?
The Biotech Showcase will run concurrently with J.P. Morgan's conference from January 12 to January 14, 2026.
How does CS1 aim to benefit patients with PAH?
CS1 is designed to target the underlying mechanisms of pulmonary arterial hypertension, showing positive results in preliminary trials in terms of safety and effectiveness.
How can I contact Cereno Scientific?
Interested parties can reach out directly through their official communication channels established for inquiries, collaborations, and discussions during biotech events.
